Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Long-term benefits for newly diagnosed patients with CML receiving first-line therapy with imatinib

06.12.2004


Responses to imatinib found to be durable at 42 months



CHU in Poitiers, France, today announced results of a study showing that newly diagnosed patients with a certain form of leukemia who are treated early with imatinib are more likely to achieve complete cytogenetic responses (the elimination of leukemic cells, a major goal of therapy) and have improved long-term outcomes.

New data from the largest study of CML patients (1106 patients included) ever conducted International Randomized IFN vs. ST1571 (IRIS) study, were presented today at the annual meeting of the American Society of Hematology (ASH). In the study, newly diagnosed patients with chronic-phase Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) who achieved cytogenetic responses early had improved rates of progression-free survival compared to those who did not achieve early responses. Responses to imatinib were shown to be durable at 42 months.


"The IRIS study continues to show durable responses in patients treated with imatinib," said Pr Francois Guilhot, Head of Oncology Hematology and Cell Therapy Department, CHU La Miletrie, Poitiers, France. "For patients who achieved the highest responses at 12 months, the probability of remaining free of the leukaemia was very high."

Study Details

The landmark analysis showed that at 42 months, 84% of patients taking imatinib remained progression free, and only 6% progressed to the more advanced disease stages (accelerated phase and blast crisis). Overall survival (based on CML-related deaths) in patients treated with imatinib was 97% at 42 months. Patients taking imatinib as first treatment who achieved a complete cytogenetic response (CcyR) within 12 months of therapy had a 93% progression free survival rate at 42 months, compared with 74% in those without CcyR. For patients who had achieved CcyR and a thousand-fold (3 log) or greater reduction in Bcr/Abl transcript level (called a molecular response) at 12 months, the probability of remaining progression free was 98% at 42 months, compared with 90% for patients with CcyR and less than a thousand-fold reduction and 75% for patients who had not achieved CcyR.

In CML, a molecular response is the disappearance or reduction in quantities of Bcr-Abl transcripts, which produce the abnormal protein responsible for driving the proliferation of white blood cells that occurs in CML patients. CHR refers to the normalization of blood counts, lasting for at least four weeks; however, the Ph chromosome positive (Ph+) cells may still be present. In McyR, less than 35% of cells containing the Philadelphia chromosome (the genetic abnormality that characterizes most cases of CML) are detected. In CcyR, Ph+ cells remain.

This study, abstract n°21, was published in Blood, Volume 104, Issue 11, November 16, 2004

About IRIS Study

IRIS: the largest Phase III CML study to date. From June 2000 to January 2001, 1106 patients were enrolled at 117 centers in 16 countries in the IRIS study (553 randomized to each treatment arm). This was the largest and most rapidly accrued phase III CML to date The IRIS study (study 106) protocol allows for a crossover in the case of lack of response, loss of response, or intolerance of treatment. After interim analysis of the trial data, the initial study protocol was amended by the Independent Data Monitoring Board (IDMB) to enable patients in either arm to cross over if no MCR had occurred after 1 year of treatment, instead of 2 years as initially required, and to enable patients in the IFN + ara-C arm to cross over to imatinib at any time, if desired.

Stéphan MARET | EurekAlert!
Further information:
http://www.chu-poitiers.fr

More articles from Studies and Analyses:

nachricht Do microplastics harbour additional risks by colonization with harmful bacteria?
05.04.2018 | Leibniz-Institut für Ostseeforschung Warnemünde

nachricht Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

Im Focus: Like a wedge in a hinge

Researchers lay groundwork to tailor drugs for new targets in cancer therapy

In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Tiny microenvironments in the ocean hold clues to global nitrogen cycle

23.04.2018 | Earth Sciences

Joining metals without welding

23.04.2018 | Trade Fair News

Researchers illuminate the path to a new era of microelectronics

23.04.2018 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>